John Frederick Ek - 08 Jul 2025 Form 4 Insider Report for Akoya Biosciences, Inc. (AKYA)

Reporting relationship: CFO
Issuer ticker: AKYA
Reported as of: 08 Jul 2025
Net transaction value: $0
SEC form: 4
Accepted by SEC: 10 Jul 2025, 20:39:37 UTC
Prior SEC filing: 03 Apr 2025
Source filing: View source filing
Reporting owner signature: /s/ John Frederick Ek

Key filing fact

John Frederick Ek filed Form 4 for Akoya Biosciences, Inc. (AKYA) on 10 Jul 2025.

Key facts

This page summarizes John Frederick Ek's Form 4 filing for Akoya Biosciences, Inc. (AKYA).
5 reported transactions and 2 derivative rows are listed below.
Accepted by SEC: 10 Jul 2025, 20:39.

Change

Previous filing in this sequence was filed on 03 Apr 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001767921 Primary reporting owner

Ek John Frederick

Relationship: CFO
Address: C/O AKOYA BIOSCIENCES, INC., 100 CAMPUS DRIVE, 6TH FLOOR, MARLBOROUGH
Signature: /s/ John Frederick Ek
Signature date: 10 Jul 2025

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

AKYA transaction

Common Stock

Other

Transaction value
Shares: -54,452
Change %: -22%
Price
Shares after: 193,750
Date: 08 Jul 2025
Ownership: Direct
Footnotes: F1, F2

AKYA transaction

Common Stock

Other

Transaction value
Shares: -193,750
Change %: -100%
Price
Shares after: 0
Date: 08 Jul 2025
Ownership: Direct
Footnotes: F1, F2, F3

AKYA transaction

Common Stock

Other

Transaction value
Shares: -20,000
Change %: -100%
Price
Shares after: 0
Date: 08 Jul 2025
Ownership: Ek Trust Dated November 20, 2020
Footnotes: F1, F2

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

AKYA transaction Derivative

Employee Stock Option (Right to Buy)

Other

Transaction value: $0
Shares: -160,000
Change %: -100%
Price: $0.000000
Shares after: 0
Date: 08 Jul 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 160,000
Exercise price: $7.60
Footnotes: F4, F5

AKYA transaction Derivative

Employee Stock Option (Right to Buy)

Other

Transaction value: $0
Shares: -70,000
Change %: -100%
Price: $0.000000
Shares after: 0
Date: 08 Jul 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 70,000
Exercise price: $5.35
Footnotes: F4, F5

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Section 16 status

John Frederick Ek is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may still apply in specific circumstances.

Explanation of responses 5 footnotes

Footnote F1

Disposition of shares pursuant to that certain Amended and Restated Agreement and Plan of Merger dated as of April 28, 2025, as amended (the "Merger Agreement"), by and among Quanterix Corporation, a Delaware corporation ("Quanterix"), Wellfleet Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Quanterix ("Merger Sub"), and Issuer. On July 8, 2025 (the "Closing Date"), Merger Sub merged with and into Issuer (the "Merger"), with Issuer surviving the Merger as a wholly owned subsidiary of Quanterix.

Footnote F2

In connection with the terms of the Merger Agreement, each share of common stock of Issuer outstanding on the Closing Date was converted into the right to receive (a) 0.1461 of a share of common stock of Quanterix (the "Per Share Stock Consideration") and (b) $0.38 in cash, without interest (the "Per Share Cash Consideration" and together with the Per Share Stock Consideration, the "Per Share Merger Consideration"). Each of the Per Share Stock Consideration and the Per Share Cash Consideration may be adjusted pursuant to the terms of the Merger Agreement.

Footnote F3

Represents aggregate share value of Issuer restricted stock units ("RSU") unvested immediately prior to the Closing Date (each individual RSU, a "Rollover RSU"). On the Closing Date, each Rollover RSU was automatically converted into the right to receive the Per Share Merger Consideration for each share of Issuer common stock subject to such Rollover RSU upon vesting, subject to the same terms and conditions of each Rollover RSU in effect immediately prior to the effectiveness of the Merger.

Footnote F4

Disposition of options pursuant to Merger Agreement.

Footnote F5

Pursuant to the Merger Agreement, as of the Closing Date, each outstanding option to purchase Issuer common stock was accelerated and each option with a per share exercise price equal to or greater than the Per Share Merger Consideration was automatically terminated and cancelled for no consideration.